What is the purpose of the study?
The purpose of the research project is to identify the genes associated with a severe and sometimes life-threatening heart-related side effect, known as myocarditis (inflammation of the heart muscle) that certain people experience when taking clozapine.
Who is needed?
- Individuals diagnosed schizophrenia/schizoaffective disorder; History of clozapine therapy for schizophrenia; History of clozapine induced myocarditis; Medical records available
Age range: 18 - 65
Gender: All
Ethnicity: All
What does the study involve?
- Number of contacts: 1 visit
- Time period: 1 day
- Length of contacts: 20 - 40 minutes
- Treatment offered: No
Study Location(s):
250 College St.
100 Stokes St. (Queen Site)
Investigator(s): Dr. Gary Remington
Contact Information:
- Phone: 416-535-8501 ext.34321
- E-mail: carol.borlido@camh.ca
Study End Date: 01 January 2027
REB number: 004/2019
Full Study Title: The Pharmogenetics of Clozapine-Induced Myocarditis
PLEASE NOTE:
- Research staff cannot give medical advice over the phone.
- If you have specific questions regarding your health care, please contact your family physician.
- We regret that not everyone screened for a study will be eligible to participate
- For more information about other treatment options for mental illness or addiction offered by CAMH, visit www.camh.ca or call 416-535-8501.